US 8,138,312 B2Granted

Compositions for regulation of tumor necrosis factor-alpha

AssigneeThe Regents of the University of Colorado, a body corporate

InventorsSoo-Hyun Kim, Charles A. Dinarello, Tania Azam

Life of this patent

Estimating the term…

Abstract

The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.

Claims4

Dependent claims

A purified human IL32 alpha protein consisting essentially of an amino acid sequence set forth in SEQ ID NO:7.

Dependencies are inferred from the claim text.

Facts

Application: 12/482,987Filed 11 Jun 2009 · division
Priority: 9 Nov 2006
Published: US 2011/0190476 A14 Aug 2011
Granted: 20 Mar 2012
Term ends: Not estimatedThe source records don’t support an estimate.

Classification32 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

Application10/578,943Parent of this division · filed 9 Nov 2006
US 2011/0190476 A1Pre-grant publication · published 4 Aug 2011
US 7,560,265 B2Parent of this division
US 2007/0071719 A1Published application
US 8,138,312 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results